Google NewsNeuren Pharmaceuticals (ASX:NEU): H1 Results, DAYBUE Growth and Dividend Explained - Kalkine
Neuren Pharmaceuticals (ASX:NEU): H1 Results, DAYBUE Growth and Dividend Explained Kalkine
Neuren Pharmaceuticals (NEU) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Neuren Pharmaceuticals (ASX:NEU) Shares Trade On Premium Despite Margin Compression - simplywall.st
Neuren Pharmaceuticals (ASX:NEU) Shares Trade On Premium Despite Margin Compression simplywall.st
Motley FoolBuy, hold, sell: Whitehaven, Endeavour, Neuren Pharmaceuticals shares
As earnings season continues, brokers have updated their ratings and 12-month price targets. The post Buy, hold, sell: Whitehaven, Endeavour, Neuren Pharmaceuticals shares appeared first on The Motley Fool Australia.
ASXGrowing royalty anchors Neuren first ever dividend program
earnings announcement
Neuren share price in focus after DAYBU wins EU approval for Rett syndrome
Neuren shares are on watch after DAYBU (trofinetide) won European approval, unlocking commercial milestones and revenue opportunities. The post Neuren share price in focus after DAYBU wins EU approval for Rett syndrome appeared first on The Motley Fool Australia.
European Commission grants marketing authorisation for DAYBU
other announcement
Neuren H1 2026 Financial Results Webinar on 26 August 2026
other announcement
Neuren Pharmaceuticals (ASX:NEU) Shares in Focus as DAYBUE Growth Supports Higher Royalty Outlook - Kalkine
Neuren Pharmaceuticals (ASX:NEU) Shares in Focus as DAYBUE Growth Supports Higher Royalty Outlook Kalkine
Neuren Pharmaceuticals (ASX:NEU) Dips as Investors Monitor Commercial and Clinical Progress - Kalkine
Neuren Pharmaceuticals (ASX:NEU) Dips as Investors Monitor Commercial and Clinical Progress Kalkine
Neuren Pharmaceuticals (ASX:NEU) Shares Under Pressure as Investors Track the Biotechnology Landscape - Kalkine
Neuren Pharmaceuticals (ASX:NEU) Shares Under Pressure as Investors Track the Biotechnology Landscape Kalkine
KalkineNeuren Pharmaceuticals (ASX:NEU) in Focus on Biotech Progress
Highlights Neuren Pharmaceuticals is drawing attention today around biotechnology progress. The update gives the sector a fresh company-specific news hook. Execution and wider market conditions remain central to the next read-through. Neuren Pharmaceuticals (ASX:NEU) is in focus today as the Australian market weighs biotechnology progress, putting the companys latest operational narrative at the centre of a busy local trading session. Why the update matters now The immediate reaction matters ...
Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?
This healthcare stock keeps rising. The post Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%? appeared first on The Motley Fool Australia.
Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade
Second quarter net sales of DAYBUE increased 30%. The post Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade appeared first on The Motley Fool Australia.
Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
other announcement
Why Neuren Pharmaceuticals (ASX: NEU) Stock Is Rising Today? - Kalkine
Why Neuren Pharmaceuticals (ASX: NEU) Stock Is Rising Today? Kalkine
Neuren Pharmaceuticals (ASX:NEU) Climbs Against the Market—Can the Momentum Continue? - Kalkine
Neuren Pharmaceuticals (ASX:NEU) Climbs Against the Market—Can the Momentum Continue? Kalkine
Neuren highlights participation in PMSF Family Conference
other announcement
Neuren Pharmaceuticals (ASX:NEU) Draws Investor Attention After Recent Decline - Kalkine
Neuren Pharmaceuticals (ASX:NEU) Draws Investor Attention After Recent Decline Kalkine
Neuren Pharmaceuticals (ASX:NEU) US$35m EU trigger puts royalties back in focus - Stocks Down Under
Neuren Pharmaceuticals (ASX:NEU) US$35m EU trigger puts royalties back in focus Stocks Down Under
Neuren Pharmaceuticals (ASX:NEU) Draws Attention as Drug Pipeline Strengthens
Highlights Neuren Pharmaceuticals continues advancing its rare neurological disease pipeline while attracting renewed market attention. Progress across commercial licensing and late-stage clinical development remains central to the company's long-term strategy. Investors continue monitoring regulatory milestones, clinical trials and future commercial opportunities. Neuren Pharmaceuticals continues advancing its rare disease pipeline as clinical development, li...
ASX 200 Set for Monday Focus: Will Neuren (ASX:NEU) and Gold Stocks Lead the Market?
Highlights The Australian share market is expected to begin the week on a positive note despite mixed overseas trading. Commodity prices, broker updates and dividend adjustments are likely to influence early market activity. Gold miners, energy companies and several dividend-paying shares remain closely watched. The Australian share market is preparing for another active trading session after ending last week with modest gains. Investors will be watching globa...
DAYBU recommended for approval in the European Union
other announcement
NEU (ASX:NEU) DAYBUE Royalties Lift Growth as Sales Rise
Highlights NEU (ASX:NEU) reports around growth in net sales and royalty income, driven by DAYBUE traction. Commercial partner expansion continues to support Rett syndrome treatment uptake. Market attention builds around biotech earnings visibility within the [ASX 200] healthcare sector. NEU (ASX:NEU) continues to grow royalty income from DAYBUE, with rising sales reinforcing its position as a key biotech name in the ASX healthcare sector. Australian healthcare stocks continue to attract...
Why Is ASX:NEU Waiting on Europe Daybue Decision Shock?
Highlights Neuren Pharmaceuticals (ASX:NEU) is in focus as its partner awaits a key European regulatory decision on Daybue. Strong North American uptake of the therapy continues to underpin royalty-linked revenue expectations. The outcome could reshape the commercial pathway for Rett syndrome treatment expansion. Neuren Pharmaceuticals is in focus as a European decision on Daybue approaches, with North American success underpinning its rare disease growth narrative and global expansion ...
Neuren Pharmaceuticals (ASX:NEU): Biotech Growth Stock Returns to Market Conversation - Kalkine
Neuren Pharmaceuticals (ASX:NEU): Biotech Growth Stock Returns to Market Conversation Kalkine
Neuren Pharmaceuticals (ASX:NEU) Gains Momentum as Investors Track Pipeline and Commercial Progress - Kalkine
Neuren Pharmaceuticals (ASX:NEU) Gains Momentum as Investors Track Pipeline and Commercial Progress Kalkine
Notification regarding unquoted securities - NEU
other announcement
Is Neuren (ASX:NEU) Stock Worth Watching After Its Latest DAYBUE Update? - Kalkine
Is Neuren (ASX:NEU) Stock Worth Watching After Its Latest DAYBUE Update? Kalkine
Is Neuren Pharmaceuticals (ASX:NEU) a Stock That Deserves Attention in Biotech Sector? - Kalkine
Is Neuren Pharmaceuticals (ASX:NEU) a Stock That Deserves Attention in Biotech Sector? Kalkine
Why Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch – And What's Next - simplywall.st
Why Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch – And What's Next simplywall.st
Launch of Investor Hub to enhance shareholder engagement
other announcement
Neuren Pharmaceuticals Q1 2026: DAYBUE sales soar
Neuren Pharmaceuticals posted a strong Q1 2026, with DAYBUE net sales and royalty income both rising more than 20% year-on-year. The post Neuren Pharmaceuticals Q1 2026: DAYBUE sales soar appeared first on The Motley Fool Australia.
Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
other announcement
DAYBUE STIX now broadly available in US for Rett syndrome
other announcement
Neuren Pharmaceuticals (ASX:NEU) Is Down 15.2% After 2025 Earnings Undershoot Expectations Has The Bull Case Changed? - simplywall.st
Neuren Pharmaceuticals (ASX:NEU) Is Down 15.2% After 2025 Earnings Undershoot Expectations Has The Bull Case Changed? simplywall.st